$7.85 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest


About HOOKIPA Pharma

HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is developing products to prevent and cure infectious diseases and cancer. The Company's infectious and oncology product candidates HB-101, HB-201 and HB-202. The infectious disease product candidate, HB-101, is in a randomized, double-blinded Phase II clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates, HB-201 and HB-202, are in development for the treatment of human papillomavirus-positive cancers. The Company offers VaxWave technology, which is designed to induce a robust CD8+ T cell and pathogen neutralizing response to fight disease. VaxWave technology supports the benefits of our arenavirus platform approach.

Stock Analysis

last close $7.85
1-mo return -14.4%
3-mo return -37.5%
avg daily vol. 331.98T
52-week high 20
52-week low 7.35
market cap. $193M
forward pe -
annual div. -
roe -40.5%
ltg forecast -
dividend yield -
annual rev. $21M
inst own. 66.6%

Subscribe now for daily local and international financial news